Chimeric Antigen Receptor T Cell Therapy for Solid Tumors: Current Status, Obstacles and Future Strategies

Chimeric antigen receptor T cells (CAR T Cells) have led to dramatic improvements in the survival of cancer patients, most notably those with hematologic malignancies. Early phase clinical trials in patients with solid tumors have demonstrated them to be feasible, but unfortunately has yielded limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Heyman, Benjamin, Yang, Yiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407020/
https://www.ncbi.nlm.nih.gov/pubmed/30736355
http://dx.doi.org/10.3390/cancers11020191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407020/
https://www.ncbi.nlm.nih.gov/pubmed/30736355
http://dx.doi.org/10.3390/cancers11020191

Ejemplares similares